Associated Genetic Biomarkers
Multiple endocrine neoplasia I (MEN1) is a gene that encodes menin. Menin is a tumor suppressor protein that functions in the inhibition of transcriptional activation. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame deletions and insertions are observed in cancers such as parathyroid cancer, retroperitoneal cancer, and thymus cancer.
MEN1 is altered in 1.38% of all cancers with pancreatic neuroendocrine neoplasm, breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in MEN1 are MEN1 Mutation (1.48%), MEN1 Loss (0.13%), MEN1 Amplification (0.10%), MEN1 R521Gfs*43 (0.08%), and MEN1 I85Sfs*33 (0.03%) .
MEN1 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain MEN1 status as an inclusion criterion, 1 is phase 2 (1 open) and 1 is phase 3 (1 open).
Trials with MEN1 status in the inclusion eligibility criteria most commonly target bladder carcinoma, multiple endocrine neoplasia type 1, and urothelial carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is MEN1 Mutation .
Observation, olaparib, and somatostatin analog therapy are the most frequent therapies in trials with MEN1 as an inclusion criteria .
Significance of MEN1 in Diseases
Urothelial Carcinoma +
Bladder Carcinoma +
Multiple Endocrine Neoplasia Type 1 +
MEN1 is an inclusion criterion in 1 clinical trial for multiple endocrine neoplasia type 1, of which 1 is open and 0 are closed. Of the trial that contains MEN1 status and multiple endocrine neoplasia type 1 as inclusion criteria, 1 is phase 3 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.